Regulatory T-cells in Psoriasis Patients as Targets for Therapy

Sponsor
University of Aberdeen
Study ID
NCT01233583
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • Dovobet, neotigason, etanercept, adalimumab. infliximab — DRUG
    Dovobet ointment 15g/day for 6 weeks Neotigason capsule 50mg per day (oral) for 6 weeks Enbrel 50mg twice weekly subcutaneous injection for 6 weeks Humira 80mg week 0, 40 mg week 1 then every other week therafter subcutaneous injection for 6 weeks Remicade 3 separate doses of 5mg/kg intavenous injection for 6 weeks

Study Details

The aim of this study is to understand which therapies will suppress effector cells and promote regulatory T cells and To test whether patients with a better response to therapy and longer psoriasis-free periods develop a higher numerical ratio of regulatory to effectors T-cells and/or regulatory cells more able to suppress the effectors.

Key Dates

Start date
Jun 30, 2010
Status verified
Dec 2014
Primary completion
Sep 30, 2013
Completion
Sep 30, 2013

Study Design

Enrollment
38 participants (actual)

Arms

  • Arm: Betamethasone/Calcipotriol (Dovobet)
    patients in whom decision to treat with Dovobet by their dermatologist
  • Arm: Acitretin (neotigason)
    patients in whom decision to treat with neotigason by their dermatologist
  • Arm: narrow-band UVB
    patients in whom decision to treat with narrow band UVB by their dermatologist
  • Arm: Anti TNF-alpha
    patients in whom decision to treat with anti TNF-alpha(adalimumab-etanercept-infliximab) by their dermatologist

Primary Outcome Measure

Clincal-immunological correlation of treatment outcome in psoriasis patients [ Time Frame: 12 months ]

Related Studies